A novel peptide inhibitor of classical and lectin complement activation including ABO incompatibility

Molecular Immunology

Volumn 53, Issue 1-2, 2013, Pages 132-139

  Mauriello, Clifford T ^a   Pallera, Haree K ^b   Sharp, Julia A ^a   Woltmann, Jon L ^a   Qian, Shizhi ^b   Hair, Pamela S ^a   van der Pol, Pieter ^c   van Kooten, Cees ^c   Thielens, Nicole M ^d   Lattanzio, Frank A ^a   Cunnion, Kenji M ^a,e   Krishna, Neel K ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b OLD DOMINION UNIVERSITY   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^e Children's Specialty Group   (United States)

Author keywords

ABO incompatibility; C1q; Coat protein; Complement; MBL; Peptides

Indexed keywords

AMINO ACID DERIVATIVE; BINDING PROTEIN; BIOTIN; COAT PROTEIN; COLLAGEN LIKE REGION; COMPLEMENT COMPONENT C1Q; E23A PEPTIDE; GLOBULAR HEAD REGION; MANNOSE BINDING LECTIN; POLAR ASSORTANT PEPTIDE; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; COMPLEMENT ACTIVATION; ENZYME BINDING; HEMOLYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; RAT; SURFACE PLASMON RESONANCE;

ABO BLOOD-GROUP SYSTEM; AMINO ACID SEQUENCE; ANIMALS; BLOOD GROUP INCOMPATIBILITY; CAPSID PROTEINS; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; HUMANS; PEPTIDES; RATS; SURFACE PLASMON RESONANCE;

ANIMALIA; HUMAN ASTROVIRUS; RATTUS; RODENTIA;

EID: 84865060611     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.07.012     Document Type: Article

References (18)

1. Bonaparte R.S., Hair P.S., Banthia D., Marshall D.M., Cunnion K.M., Krishna N.K. Human astrovirus coat protein inhibits serum complement activation via C1, the first component of the classical pathway. Journal of Virology 2008, 82:817-827.
2. Cunnion K.M., Lee J.C., Frank M.M. Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infection and Immunity 2001, 69:6796-6803.
3. Groeneveld T.W.L., Ramwadhdoebé T.H., Trouw L.A., van den Ham D.L., van der Borden V., Drijfhout J.W., Hiemstra P.S., Daha M.R., Roos A. Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. Molecular Immunology 2007, 44:3608-3614.
4. Gronemus J.Q., Hair P.S., Crawford K.B., Nyalwidhe J.O., Cunnion K.M., Krishna N.K. Potent inhibition of the classical pathway of complement by a novel C1q-binding peptide derived from the human astrovirus coat protein. Molecular Immunology 2010, 48:305-313.
5. Hair P.S., Gronemus J.Q., Crawford K.B., Salvi V.P., Cunnion K.M., Thielens N.M., Arlaud G.J., Rawal N., Krishna N.K. Human astrovirus coat protein binds C1q and MBL and inhibits the classical and lectin pathways of complement inhibition. Molecular Immunology 2010, 47:792-798.
6. Janatpour K.A., Kalmin N.D., Jensen H.M., Holland P.V. Clinical outcomes of ABO-incompatible RBC transfusions. American Journal of Clinical Pathology 2008, 129:276-281.
7. Köhl J. Self, non-self, and danger: a complementary view. Advances in Experimental Medicine and Biology 2006, 586:71-94.
8. Myszka D.G. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Current Opinion in Biotechnology 1997, 8:50-57.
9. Phillips A.E., Toth J., Dodds A.W., Girija U.V., Furze C.M., Pala E., Sim R.B., Reid K.B.M., Schwaeble W.J., Schimd R., Keeble A.H., Wallis R. Analogous interactions in initiating complexes of the classical and lectin pathways of complement. Journal of Immunology 2009, 182:7708-7717.
10. Pruss A., Salama A., Ahrens N., Hansen A., Kiesewetter H., Koscielny J., Dörner T. Immune hemolysis - serological and clinical aspects. Clinical and Experimental Medicine 2003, 3:55-64.
11. Ricklin D., Lambris J.D. Complement-targeted therapeutics. Nature Biotechnology 2007, 25:1265-1275.
12. Ricklin D., Lambris J.D. Compstatin: a complement inhibitor on its way to clinical application. Advances in Experimental Medicine and Biology 2008, 632:273-292.
13. Roberts I.A. The changing face of haemolytic disease of the newborn. Early Human Development 2008, 84:515-523.
14. Roos A., Nauta A.J., Broers D., Faber-Krol M.C., Trouw L.A., Drijfhout J.W., Daha M.R. Specific inhibition of the classical complement pathway by C1q-binding peptides. Journal of Immunology 2001, 93:942-951.
15. Schreiber A.D. Autoimmune hemolytic anemia. The Human Complement System in Health and Disease 1998, 547-569. Marcel Dekker, Inc., New York, NY. 1st ed. J.E. Volanakis, M.M. Frank (Eds.).
16. Strobel E. Hemolytic transfusion reactions. Transfusion Medicine and Hemotherapy 2008, 35:346-353.
17. Thayyil S., Milligan D.W. Single versus double volume exchange transfusion in jaundiced newborn infants. Cochrane Database of Systematic Reviews 2006, 4:CD004592.
18. Thielens N.M., Bally I.M., Ebenbichler C.F., Dierich M.P., Arlaud G.J. Further characterization of the interaction between the C1q subcomponent of C1 and the transmembrane envelope glycoprotein gp41 of HIV-1. Journal of Immunology 1993, 151:6583-6592.